Valuation: Fennec Pharmaceuticals Inc.

Market Cap 411M 352M 331M 302M 570M 39.17B 573M 3.91B 1.52B 19.76B 1.54B 1.51B 65.44B P/E 2026 *
37.7x
P/E 2027 * 12.3x
Enterprise Value 411M 352M 331M 302M 570M 39.17B 573M 3.91B 1.52B 19.76B 1.54B 1.51B 65.44B EV / Sales 2026 *
5.63x
EV / Sales 2027 * 3.98x
Free-Float
80.4%
Yield 2026 *
-
Yield 2027 * -
1 day+3.93%
1 week+2.53%
Current month+27.17%
1 month+21.82%
3 months+22.56%
6 months+37.20%
Current year+58.05%
1 week 10.88
Extreme 10.88
12.28
1 month 9.4
Extreme 9.3959
13.25
Current year 5.65
Extreme 5.65
13.25
1 year 5.65
Extreme 5.65
13.25
3 years 3.96
Extreme 3.96
13.25
5 years 3.82
Extreme 3.8219
13.25
10 years 1.64
Extreme 1.6439
14.99
Manager TitleAgeSince
Chief Executive Officer 64 2024-08-15
Director of Finance/CFO 51 2010-01-05
Chief Tech/Sci/R&D Officer 51 2024-10-27
Director TitleAgeSince
Director/Board Member 72 2011-08-24
Chairman 69 2015-12-08
Director/Board Member 70 2016-08-09
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Buy

Chief Technology Officer

168 0.0005%
8/3/26 Buy

Executive/Senior Manager

168 0.0005%
8/3/26 Sell -10,000 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
+3.93%+2.53%+40.69%+48.41% 411M
-3.59%-2.96%+71.06%+114.83% 1,100B
-1.15%-0.41%+51.34%+62.41% 658B
-1.09%+1.54%+26.67%+79.22% 470B
-1.47%+2.05%+41.71%+42.09% 372B
-0.90%+1.29%+25.62%+41.75% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.43%+3.54%+52.65%+71.75% 239B
-0.93%+2.90%-16.98%-52.28% 213B
-0.46%+3.24%+29.73%+92.67% 184B
Average -0.76%+2.57%+32.55%+51.41% 380.33B
Weighted average by Cap. -1.77%+2.21%+42.86%+68.24%

Financials

2026 *2027 *
Net sales 72.9M 62.57M 58.73M 53.64M 101M 6.95B 102M 695M 269M 3.51B 274M 268M 11.62B 103M 88.54M 83.1M 75.9M 143M 9.84B 144M 983M 381M 4.96B 387M 379M 16.44B
Net income 11.25M 9.65M 9.06M 8.27M 15.62M 1.07B 15.69M 107M 41.55M 541M 42.23M 41.31M 1.79B 35.24M 30.24M 28.39M 25.93M 48.93M 3.36B 49.16M 336M 130M 1.7B 132M 129M 5.62B
Net Debt - -
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Employees
35
Date Price Change Volume
26-08-26 US$12.17 +3.93% 250,551
26-08-25 US$11.71 +2.72% 198,353
26-08-24 US$11.40 +0.97% 218,904
26-08-21 US$11.29 -0.53% 210,738
26-08-20 US$11.35 -4.38% 246,211
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.17USD
Average target price
17.67USD
Spread / Average Target
+45.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FENC Stock